Superb Scientists
Israel has the highest concentration of scientists and physicians per capita
Help us reach our goal of $5.4M!
Why ICRF?
Cost-effective research
Funding scientists in Israel has 30% less overhead costs than North American research
Institution Neutral
Funding goes to scientists at all of Israel's top biomedical research centers
Targeted Funding
ICRF directly funds individual vetted scientists, rather than "bricks and mortar"
ICRF Funded Researcher publishes paper in Nature
Yinon Ben-Neriah, ICRF Funded Researcher publishes paper in Nature: The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer.
Preview article here.
New approach for overcoming melanoma's resistance to anti-cancer drugs
Melanoma often presents a rapid resistance to molecular anti-cancer therapies. Although there have been advances in targeted and immunotherapy melanoma treatments in recent years, a substantial percentage of patients fail to respond or develop resistance to such therapies. Read article here.
Yinon Ben-Neriah, ICRF Funded Researcher publishes paper in Nature: The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer.
Preview article here.
HELP US FUND CANCER RESEARCH!
Scientific Discoveries
p53 gene tumor suppressor
Demonstrated that the p53 end acts as a tumor suppressor - one of the hallmark discoveries in cancer in the 20th century.
The Philadelphia Chromosome
Identified the structure of the Philadelphia Chromosome, the first genetic linkage identified in leukemia. This lead to the development of Gleevec, one of the first targeted cancer therapies.
Doxil®
This cancer drug works overtime to treat ovarian, breast and AIDS-related cancers.
RAD 51
Used to identify the likelihood of breast cancer occurring in women who carry the BRCA 2 gene.
The Ubiquitin System
Our discovery led to development of the miracle drug Velcade® for treatment of multiple myeloma.
Israel Winning the Nobel Prize
ICRF-funded professors Avram Hershko and Aaron Ciechanover won for their discovery of the ubiquitin system. Their research resulted in the development of the drug Velcade® named “The Top Medical Breakthrough of 2003” by the Wall Street Journal.
Improved Cancer Treatment
ICRF scientists have discovered improved chemo-therapies and advanced techniques in bone marrow transplantation that have improved the survival rates and eased the suffering of many people battling cancer.
Events
Date to be confirmed
Revolving Tables
Thank you to our sponsors, donors and attendees for making t...
view event
Date to be confirmed
George Knudson Oakdale Golf Tournament
In memory of George Knudson, golf for the cure this year! ...
view event
Date to be confirmed
ICRF Presents: Legends of the Halftime Show
ICRF Presents: Legends of the Halftime Show raised over $655...
view event
Date to be confirmed
Bike for the Fight!
Thank you for another successful year of Bike for the Fight!...
view event
Date to be confirmed
21st Annual Women of Action Celebration
Thank you for helping us raise over $800,000 for our cancer ...
view event